Selected Publication:

SHR Neuro Cancer Cardio Lipid Metab Microb

Obermayer, A; Tripolt, NJ; Pferschy, PN; Kojzar, H; Jacan, A; Schauer, M; Aziz, F; Oulhaj, A; Aberer, F; Sourij, C; Obermayer-Pietsch, B; Stadlbauer, V; Sourij, H.
INTERmittent FASTing in people with insulin-treated type 2 diabetes mellitus - the INTERFAST-2 study protocol.
Diabet Med. 2022; 39(6):e14813 Doi: 10.1111/dme.14813 [OPEN ACCESS]
Web of Science PubMed FullText FullText_MUG

 

Leading authors Med Uni Graz

Obermayer Anna Maria Antonia

Sourij Harald

Co-authors Med Uni Graz

Aberer Felix

Aziz Faisal

Jacan Angela

Kojzar Harald

Obermayer-Pietsch Barbara

Pferschy Peter

Schauer Markus

Sourij Caren

Stadlbauer-Köllner Vanessa

Tripolt Norbert

Altmetrics:

Dimensions Citations:

Plum Analytics:

Scite (citation analytics):

Abstract:

AIM: Intermittent fasting, a dietary intervention of alternate eating and fasting, has gained popularity in people trying to lose weight. Intermittent fasting could provide an alternative to classic caloric restriction in people with type 2 diabetes mellitus. The aim of the study is to determine the impact of a 12-week intermittent fasting regimen compared with usual care in people with type 2 diabetes mellitus receiving insulin therapy. METHODS: This open, single-centre, randomized controlled trial investigates participants with type 2 diabetes mellitus on insulin therapy and a glycated haemoglobin A1c (HbA1c) of ≥53 mmol/mol (≥7.0%) and a minimum insulin dose of 0.3 IU/kg body weight per day. Participants are randomized in a 1:1 ratio to either 12 weeks of intermittent fasting or the standard care group. All participants receive dietary counselling, continuous glucose monitoring, measurement of the resting metabolic rate, an oral glucose tolerance test, body composition measurement via dual-energy X-ray absorptiometry and stool samples for microbiome analyses at the beginning and at the end of the intervention. Two co-primary outcomes (analysed in hierarchical order) were chosen for the study: (i) the difference in the change of HbA1c from baseline to 12 weeks and (ii) the difference in the number of participants achieving a combined end point encompassing a body weight reduction of at least 2%, an insulin dose reduction of at least 10% and an absolute HbA1c reduction of at least 3 mmol/mol (0.3%) between the two groups.

Find related publications in this database (using NLM MeSH Indexing)

Blood Glucose - metabolism

Blood Glucose Self-Monitoring - administration & dosage

Diabetes Mellitus, Type 2 - drug therapy

Fasting - administration & dosage

Glycated Hemoglobin A - metabolism

Humans - administration & dosage

Hypoglycemic Agents - therapeutic use

Insulin - metabolism, therapeutic use

Randomized Controlled Trials as Topic - administration & dosage

Find related publications in this database (Keywords)

insulin sensitivity

insulin therapy

Intermittent fasting

type 2 diabetes mellitus (T2DM)

weight loss

© Med Uni Graz • Imprint